{"prompt": "['Novartis', 'Confidential', 'Page 79', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'Reiss TF, Chervinsky P, Dockhorn RJ et al (1998) Montelukast, a once-daily leukotriene', 'receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-', 'blind trial. Montelukast Clinical Research Study Group. Arch Intern Med; 158:1213-1220.', 'Santanello NC, Barber BL, Reiss TF et al (1997) Measurement characteristics of two asthma', 'symptom diary scales for use in clinical trials. Eur Resp J; 10: 646-651.']['Novartis', 'Confidential', 'Page 80', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', '13', 'Appendix 1: Clinically notable laboratory values and vital', 'signs', 'The central laboratory will flag laboratory values falling outside of the normal ranges on the', 'central laboratory reports. Investigators are responsible for reviewing these abnormal values', 'for clinical significance, signing the laboratory reports to indicate their review, and reporting', 'values considered clinically significant in the appropriate electronic case report form (eCRF).', 'Any clinically significant abnormal laboratory value should be evaluated and followed-up by', 'the investigator until normal or a cause for the abnormality is determined.', 'See Appendix 2 for specific liver event and laboratory test trigger definitions and follow-', 'up requirements. See Appendix 3 for specific renal alert criteria and actions.', 'For electrocardiograms (ECGs), a notable QTc value is defined as a QTcF (Fridericia) interval', 'of >450 msec for males or >460 msec for females - all such ECGs will be flagged by the', 'Central contract research organization (CRO) and require assessment for clinical relevance', 'and continuance of the patient by the Investigator.']['Novartis', 'Confidential', 'Page 81', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', '14', 'Appendix 2: Liver event and laboratory trigger definitions', 'and follow-up requirements', 'Table 14-1', 'Liver Event and Laboratory Trigger Definitions', 'Definition/ threshold', 'LIVER LABORATORY TRIGGERS', '3 x ULN < ALT / AST < 5 X ULN', '1.5 X ULN < TBL < 2 X ULN', 'LIVER EVENTS', 'ALT or AST > 5 x ULN', 'ALP > 2 x ULN (in the absence of known bone pathology)', 'TBL > 2 x ULN (in the absence of known Gilbert syndrome)', 'ALT or AST > 3 x ULN and INR > 1.5', \"Potential Hy's Law cases (defined as ALT or AST > 3 x ULN and\", 'TBL > 2 x ULN [mainly conjugated fraction] without notable increase in', 'ALP to > 2 x ULN)', 'Any clinical event of jaundice (or equivalent term)', 'ALT or AST > 3 x ULN accompanied by (general) malaise, fatigue,', 'abdominal pain, nausea, or vomiting, or rash with eosinophilia', 'Any adverse event potentially indicative of a liver toxicity*', '*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-related', 'conditions; the non-infectious hepatitis; the benign, malignant and unspecified liver neoplasms.', 'Abbreviations: ULN (upper limit of normal), ALT (alanine aminotransferase), AST (aspartate aminotransferase),', 'TBL (total bilirubin), ALP (alkaline phosphatase), INR (international normalized ratio).', 'Table 14-2', 'Follow Up Requirements for Liver Events and Laboratory Triggers', 'Criteria', 'Actions required', 'Follow-up monitoring', \"Potential Hy's Law\", 'Discontinue the study treatment immediately', 'ALT, AST, TBL, Alb, PT/INR, ALP and', 'casea', 'Hospitalize, if clinically appropriate', 'yGT until resolution\u00b0 (frequency at', 'Establish causality', 'investigator discretion)', 'Complete liver CRF', 'ALT or AST', '> 8 x ULN', 'Discontinue the study treatment immediately', 'ALT, AST, TBL, Alb, PT/INR, ALP and', 'Hospitalize if clinically appropriate', 'yGT until resolution (frequency at', 'Establish causality', 'investigator discretion)', 'Complete liver CRF', '>', '3 x ULN and INR >', 'Discontinue the study treatment immediately', 'ALT, AST, TBL, Alb, PT/INR, ALP and', '1.5', 'Hospitalize, if clinically appropriate', 'yGT until resolution\u00b0 (frequency at', 'Establish causality', 'investigator discretion)', 'Complete liver CRF', '> 5 to 8 x ULN', 'Repeat LFT within 48 hours', 'ALT, AST, TBL, Alb, PT/INR, ALP and', 'If elevation persists, continue follow-up', 'yGT until resolution\u00b0 (frequency at', 'monitoring', 'investigator discretion)', 'If elevation persists for more than 2 weeks,', 'discontinue the study drug', 'Establish causality', 'Complete liver CRF', '> 3 x ULN', 'Discontinue the study treatment immediately', 'ALT, AST, TBL, Alb, PT/INR, ALP and', 'accompanied by', 'Hospitalize if clinically appropriate', 'yGT until resolution\u00b0 (frequency at', 'symptomsb', 'investigator discretion)']\n\n###\n\n", "completion": "END"}